Botulinum toxin A for drooling in Parkinson's disease: A pilot study to compare submandibular to parotid gland injections

Background/Aim. Botulinum toxin-A (BTX-A) is known to block the release of acetylcholine from motor and autonomic nerve terminals and may significantly decrease saliva production when injected intraglandulary. The aim of this study was to evaluate effects of BTX-A injections in the treatment of disabling sialorrhea in various neurological disorders. Methods. This study included 19 consecutive patients with significant sialorrhea associated with various neurological disorders. Out of them 13 patients were with Parkinson's disease, two with pantothenate kinase-associated neurodegeneration, two with multiple system atrophy, one with Wilson's disease, and one patient with postoperative sialorrhea. Botulinum toxin-A (Dysport?, Ipsen Pharma) was injected into the parotid glands with (n = 7 patients) or without (n = 12 patients) ultrasound guidance. All the patients were scored before and after the treatment and in weekly intervals thereafter using the salivation item of the part II (Activities of Daily Living) of the Unified Parkinson's Disease Rating Scale (UPDRS). Results. Thirteen patients (68%) reported beneficial effect of BTX-A injection, while 6 of them (32%) had no response at all. The sialorrhea scores before and after the treatment were 3.1 ? 0.1 (range 2-4) and 1.8 ? 0.1 (range 0- 3), respectively (t = 5.636; p < 0.001). There was no difference in the magnitude of response between the groups with (t = 4.500; p = 0.004) and without (t = 3.674; p = 0.005) ultrasound control of injection sites. Adverse effects were registered in 5 patients (26%). Conclusions. Botulinum toxin-A injections to easily accessible parotid glands, without necessity for ultrasound guidance, are safe and efficaceous treatment for sialorrhea in different neurological disorders.

Download Full-text

P2.115 Botulinum toxin B vs. botulinum toxin A for the treatment of sialorrhea in Parkinson's disease and amyotrophic lateral sclerosis

Parkinsonism & Related Disorders ◽

10.1016/s1353-8020(09)70466-3 ◽

2009 ◽

Vol 15 ◽

pp. S120

Author(s):

R. Ash ◽

S. Ku ◽

J. Grace ◽

J.L. Ostrem ◽

G.A. Glass

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Amyotrophic Lateral Sclerosis ◽

Botulinum Toxin ◽

Botulinum Toxin A ◽

Toxin A ◽

Toxin B ◽

Botulinum Toxin B ◽

Lateral Sclerosis

Download Full-text

Subtrigonal Botulinum toxin-A (BoNT-A) therapy for female patients with OAB combined with urethral instability - results of a pilot study

10.26226/morressier.59b63e41d462b8029238974d ◽

2017 ◽

Author(s):

Janneke van

Keyword(s):

Botulinum Toxin ◽

Pilot Study ◽

Botulinum Toxin A ◽

Toxin A ◽

Female Patients ◽

Urethral Instability

Download Full-text

Effects of Onabotulinum Toxin A on Gait in Parkinson’s Disease Patients with Foot Dystonia

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ◽

10.1017/cjn.2021.42 ◽

2021 ◽

pp. 1-6

Author(s):

Pei Huang ◽

Yuan-Yuan Li ◽

Jung E. Park ◽

Ping Huang ◽

Qin Xiao ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Botulinum Toxin ◽

Gait Analysis ◽

Rating Scale ◽

Analog Scale ◽

Toxin A ◽

Timed Up And Go ◽

Balance Test ◽

Onabotulinum Toxin A

ABSTRACT: We investigated the effects of botulinum toxin on gait in Parkinson’s disease (PD) patients with foot dystonia. Six patients underwent onabotulinum toxin A injection and were assessed by Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS), visual analog scale (VAS) of pain, Timed Up and Go (TUG), Berg Balance Test (BBT), and 3D gait analysis at baseline, 1 month, and 3 months. BFMDRS (p = 0.002), VAS (p = 0.024), TUG (p = 0.028), and BBT (p = 0.034) were improved. Foot pressures at Toe 1 (p = 0.028) and Midfoot (p = 0.018) were reduced, indicating botulinum toxin’s effects in alleviating the dystonia severity and pain and improving foot pressures during walking in PD.

Download Full-text